Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
成纤维细胞生长因子 1 预防高脂血症和动脉粥样硬化
基本信息
- 批准号:10345440
- 负责人:
- 金额:$ 55.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-01 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:Adipose tissueAgonistAnimal ModelApolipoprotein EArterial Fatty StreakArteriesAtherosclerosisAttenuatedBiliaryBinding SitesBloodCardiovascular DiseasesCell ProliferationCellsCholesterolCholesterol HomeostasisChronicClinicalClinical ResearchCoagulation ProcessDataDevelopmentDiabetes MellitusDoseDyslipidemiasEngineeringEnterocytesFGF1 geneFecesFluoresceinFutureGenetic TranscriptionHeparin BindingHepaticHepatocyteHumanHyperlipidemiaIntestinal AbsorptionIntestinesKnockout MiceLDL Cholesterol LipoproteinsLabelLeadLife StyleLipidsLiverMediatingMediator of activation proteinMetabolicMetabolic syndromeMutationNon-Insulin-Dependent Diabetes MellitusNuclear TranslocationOperative Surgical ProceduresOrganOrganoidsPathogenesisPathologicPatientsPhenotypePlayPrevention approachRadioisotopesRecombinantsRegulationRiskRisk FactorsRoleSiteTestingTherapeuticUp-RegulationVariantangiogenesisatherogenesisblood glucose regulationcholesterol absorptioncholesterol biosynthesisclinical practicedb/db mousedietaryinsightmacrophageneovascularizationnon-alcoholic fatty liver diseasenovelnovel strategiesnovel therapeutic interventionoverexpressionpreventside effecttranscription factortranslational potentialtumorigenic
项目摘要
Atherosclerosis is a narrowing of arteries caused by plaque buildup. Dyslipidemia, especially elevated low-
density lipoprotein cholesterol, is a major risk factor for atherosclerotic plaque formation. Current therapies for
atherosclerosis focus on lowering cholesterol. However, conventional lipid lowering therapies (such as statins)
are associated with obvious side effects. Developing more specific and efficient treatments are needed.
Fibroblast growth factor 1 (FGF1) has been widely studied for its therapeutic benefits in cardiovascular disorders
primary utilization of its mitogenic functions. Recently, FGF1 was shown to exert an unexpected metabolic activity
by regulating adipose remodeling and glucose homeostasis, demonstrating a potential for treatment of metabolic
syndrome. However, wild-type FGF1 (FGF1WT) induced hyperproliferation can lead to increased tumorigenic risk;
this becomes the primary obstacle for its widespread application. To reduce this risk, we recently engineered a
partial FGF1 agonist carrying triple mutations of the heparin-binding sites (FGF1ΔHBS), which abolished
proliferative potential, but maintains full FGF1WT metabolic activity. Notably, chronic treatment of db/db mice with
FGF1ΔHBS almost completely reversed diabetes-associated NAFLD. These findings suggest that FGF1ΔHBS is a
potentially safe and efficient therapeutic approach for treatment of metabolic syndrome.
Although characterization of the metabolic functions of FGF1 is ongoing, little is known about its roles in
atherosclerosis. A small case observation found an increased FGF1 expression in neovascularized and
macrophage-rich regions of plaque, implying a potential pathological role of FGF1 in human atherogenesis.
However, whether and how FGF1 plays beneficial or detrimental roles in atherogenesis remain unexplored. We
recently examined the impact of FGF1 administration on the pathogenesis of atherosclerosis in ApoE-KO mice
and found that FGF1ΔHBS markedly ameliorated atherosclerotic phenotypes without significant proliferative
potential in liver. Furthermore, FGF1 treatment reduced cholesterol levels in the blood, liver and intestine, but
increased cholesterol contents in feces. These preliminary data indicate that FGF1 regulation of cholesterol
homeostasis in both liver and intestine is responsible for its protection from atherosclerosis. The liver is a major
site for cholesterol biosynthesis while the intestine maintains cholesterol homeostasis by mediating intestinal
absorption of dietary and biliary cholesterol. Therefore, we hypothesize that non-mitogenic variant FGF1ΔHBS
prevents atherosclerosis by inhibiting hepatic cholesterol synthesis and suppressing intestinal
cholesterol absorption without risks of hyperproliferation. We will test the hypothesis in three specific aims:
1) Determine the roles of FGF1 in the development of atherosclerosis; 2) Determine the effects and mechanism
of FGF1 on hepatic cholesterol biosynthesis; 3) Determine the effects and mechanism of FGF1 on intestinal
cholesterol absorption. This project will provide fundamental evidence for FGF1ΔHBS acting at the hepatocytes
and intestinal enterocytes as a novel approach for the prevention of atherosclerosis in future clinical studies.
动脉粥样硬化是由斑块堆积引起的动脉狭窄。血脂异常,尤其是低脂血症
密度脂蛋白胆固醇是动脉粥样硬化斑块形成的主要危险因素。目前的治疗方法
动脉粥样硬化重点在于降低胆固醇。然而,传统的降脂疗法(如他汀类药物)
与明显的副作用相关。需要开发更具体、更有效的治疗方法。
成纤维细胞生长因子 1 (FGF1) 因其对心血管疾病的治疗作用而得到广泛研究
主要利用其促有丝分裂功能。最近,FGF1 被证明具有意想不到的代谢活性
通过调节脂肪重塑和葡萄糖稳态,展示了治疗代谢性疾病的潜力
综合症。然而,野生型 FGF1 (FGF1WT) 诱导的过度增殖可能导致致瘤风险增加;
这成为其广泛应用的首要障碍。为了降低这种风险,我们最近设计了一个
部分 FGF1 激动剂携带肝素结合位点的三重突变 (FGF1ΔHBS),从而废除了
增殖潜力,但保持完整的 FGF1WT 代谢活性。值得注意的是,对 db/db 小鼠进行长期治疗
FGF1ΔHBS 几乎完全逆转了糖尿病相关的 NAFLD。这些发现表明 FGF1ΔHBS 是
治疗代谢综合征的潜在安全有效的治疗方法。
尽管 FGF1 代谢功能的表征正在进行中,但对其在代谢中的作用知之甚少。
动脉粥样硬化。一项小病例观察发现新生血管和新生血管中 FGF1 表达增加
斑块中富含巨噬细胞的区域,这意味着 FGF1 在人类动脉粥样硬化形成中具有潜在的病理作用。
然而,FGF1 在动脉粥样硬化形成中是否以及如何发挥有益或有害作用仍有待探索。我们
最近研究了 FGF1 给药对 ApoE-KO 小鼠动脉粥样硬化发病机制的影响
并发现 FGF1ΔHBS 显着改善动脉粥样硬化表型,而没有显着的增殖作用
肝脏的潜力。此外,FGF1 治疗降低了血液、肝脏和肠道中的胆固醇水平,但
粪便中胆固醇含量增加。这些初步数据表明 FGF1 对胆固醇的调节
肝脏和肠道的稳态有助于防止动脉粥样硬化。肝脏是一个主要的
胆固醇生物合成的场所,而肠道通过介导肠道维持胆固醇稳态
饮食和胆汁胆固醇的吸收。因此,我们假设非有丝分裂变异体 FGF1ΔHBS
通过抑制肝脏胆固醇合成和抑制肠道胆固醇来预防动脉粥样硬化
胆固醇吸收而没有过度增殖的风险。我们将在三个具体目标上检验该假设:
1)确定FGF1在动脉粥样硬化发展中的作用; 2)确定效果和机制
FGF1对肝脏胆固醇生物合成的影响; 3) 确定FGF1对肠道的影响及机制
胆固醇吸收。该项目将为FGF1ΔHBS作用于肝细胞提供基础证据
和肠肠细胞作为未来临床研究中预防动脉粥样硬化的新方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yi Tan其他文献
Yi Tan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yi Tan', 18)}}的其他基金
Fibroblast growth factor 1 prevents hyperlipidemia and atherosclerosis
成纤维细胞生长因子 1 预防高脂血症和动脉粥样硬化
- 批准号:
10531887 - 财政年份:2021
- 资助金额:
$ 55.36万 - 项目类别:
A novel mechanism of stromal cell-derived factor 1 protection against diabetic cardiomyopathy
基质细胞衍生因子 1 预防糖尿病心肌病的新机制
- 批准号:
9883646 - 财政年份:2017
- 资助金额:
$ 55.36万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 55.36万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 55.36万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 55.36万 - 项目类别: